Ascentage Pharma declares first patient dosed in APG-2575 trial
Category: #health  By Nikita Chaurasia  Date: 2019-07-15
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Ascentage Pharma declares first patient dosed in APG-2575 trial

APG-2575 created by Ascentage Pharma is one of the rare Bcl-2 selective inhibitors in active clinical studies apart from Venetoclax.

Ascentage Pharma has reportedly announced that it has dosed the first patient in a phase I medical study of APG-2575, a new Bcl-2 selective inhibitor, for treating hematologic malignancies in China. The company also has a continuing multi-center phase I APG-2575 dose-escalation trial as a single agent in Australia and the United States. APG-2575 is anticipated to potentially be the first Bcl-2 inhibitor made in China.

For the record, APG-2575 is an innovative, orally managed Bcl-2 selective inhibitor. It is created to heal hematologic malignancies through selective blocking Bcl-2 to recreate the regular apoptosis process in cancer cells.

Reportedly, the founding member of the Bcl-2 family proteins is Bcl-2. The Bcl-2 family proteins are most prominent for their significant roles in regulating apoptosis by the development of heterodimers through pro-apoptotic proteins (BAD, BIM and many others). It is complicated to create a drug which affects Bcl-2 family protein due to the hydrophobic and very large Bcl-2 protein interfaces. The promoted Bcl-2 inhibitor venetoclax/ABT-199 accepted by the U.S. FDA in April 2016 has legalized the medical basis for more targeted drug development. APG-2575 created by Ascentage Pharma is one of the rare Bcl-2 selective inhibitors in active clinical studies apart from Venetoclax.

Sources claimed that the Phase I trial is created to evaluate the tolerance and safety of APG-2575 in patients enduring hematologic malignancies. The trial is also designed to check the recommended Phase II dose (RP2D) or maximal tolerated dose (MTD) of APG-2575. Patients with acute Non-Hodgkin's Lymphoma (NHL) and Acute Myelogenous Leukemia (AML) have been Included in this trial. Presently, the first enrolled patient has been medicated during the initial stage of dose-escalation.

Ascentage Pharma has reportedly released numerous preclinical research outcomes of APG-2575 during the annual meeting of 2019 American Association for Cancer Research (AACR). The results have shown the potential in combination therapy.

Source credit:

https://www.prnewswire.com/news-releases/ascentage-pharma-announces-first-patient-dosed-in-phase-i-clinical-trial-of-apg-2575-in-china-as-the-first-china-made-bcl-2-inhibitor-300884516.html

https://www.tullahomanews.com/news/business/ascentage-pharma-announces-first-patient-dosed-in-phase-i-clinical/article_8c4cdc27-db63-59f8-9ce9-dd301581f9fc.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

By Nikita Chaurasia

Mercedes-Benz, a German multinational automaker of luxury and commercial vehicles, has unveiled its flagship electric sedan, the EQS. The new vehicle is likely to allow Mercedes to take on Tesla Inc., as the market for electric vehicles (EVs) continu...

Ford takes on GM, Tesla by debuting its first hands-free driving system

Ford takes on GM, Tesla by debuting its first hands-free driving system

By Nikita Chaurasia

Ford Motor Company, the American multinational automaker, is reportedly planning on introducing a hands-free driving feature on its 2021 Mustang Models as well as 2021 F-150 pickup truck through a software update, by the end of the year. The automob...

Oculus Quest 2 update to include wireless PC streaming, 120Hz mode

Oculus Quest 2 update to include wireless PC streaming, 120Hz mode

By Nikita Chaurasia

Oculus, a subsidiary of Facebook, Inc., that develops and manufactures virtual reality headsets, has recently announced that Oculus Quest 2’s new v28 software update will include native wireless desktop PC streaming as well as 120 Hz refresh ra...